ASLAN Pharmaceuticals Ltd. (ASLN) Upgraded to Buy: What Does It Mean for the Stock? Zacks Equity Research - Zacks Investment Research - Thu Mar 26, 11:00AM CDT Zacks Equity Research - ZACKS - Thu Mar 26, 11:00AM CDT
ASLAN Pharmaceuticals Ltd. (ASLN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
ASLAN Pharmaceuticals Ltd. (ASLN) Gains But Lags Market: What You Should Know Zacks Equity Research - Zacks Investment Research - Tue Feb 4, 4:45PM CST Zacks Equity Research - ZACKS - Tue Feb 4, 4:45PM CST
ASLAN Pharmaceuticals Ltd. (ASLN) closed the most recent trading day at $2.17, moving +0.93% from the previous trading session.
Regeneron & Sanofi's sBLA for Dupixent Accepted by the FDA Zacks Equity Research - Zacks Investment Research - Tue Jan 28, 9:39AM CST Zacks Equity Research - ZACKS - Tue Jan 28, 9:39AM CST
The FDA accepts Regeneron (REGN) and Sanofi's sBLA for Dupixent for Priority Review.
Has ASLAN Pharmaceuticals (ASLN) Outpaced Other Medical Stocks This Year? Zacks Equity Research - Zacks Investment Research - Mon Jan 27, 10:30AM CST Zacks Equity Research - ZACKS - Mon Jan 27, 10:30AM CST
Is (ASLN) Outperforming Other Medical Stocks This Year?
Alexion to Start Pivotal Study on Ultomiris for ALS in Q1 Zacks Equity Research - Zacks Investment Research - Wed Jan 15, 3:34PM CST Zacks Equity Research - ZACKS - Wed Jan 15, 3:34PM CST
Alexion (ALXN) plans to initiate a phase III study on Ultomiris (ravulizumab) to treat amyotrophic lateral sclerosis.
Momenta (MNTA) Provides Pipeline Updates, Stock Rallies Zacks Equity Research - Zacks Investment Research - Wed Jan 15, 7:22AM CST Zacks Equity Research - ZACKS - Wed Jan 15, 7:22AM CST
Shares of Momenta (MNTA) rise 23.7% on pipeline updates.
Ultragenyx Provides Preliminary Crysvita 2019 Revenues Zacks Equity Research - Zacks Investment Research - Tue Jan 14, 7:53AM CST Zacks Equity Research - ZACKS - Tue Jan 14, 7:53AM CST
Ultragenyx (RARE) provides preliminary 2019 revenue numbers and 2020 outlook for Crysvita, along with other pipeline updates.
ASLAN Pharmaceuticals Ltd. (ASLN) Upgraded to Strong Buy: Here's Why Zacks Equity Research - Zacks Investment Research - Mon Jan 13, 11:00AM CST Zacks Equity Research - ZACKS - Mon Jan 13, 11:00AM CST
ASLAN Pharmaceuticals Ltd. (ASLN) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term....
Is ASLAN Pharmaceuticals (ASLN) Outperforming Other Medical Stocks This Year? Zacks Equity Research - Zacks Investment Research - Mon Jan 6, 10:30AM CST Zacks Equity Research - ZACKS - Mon Jan 6, 10:30AM CST
Is (ASLN) Outperforming Other Medical Stocks This Year?
Will ASLAN Continue to Surge Higher? Zacks Equity Research - Zacks Investment Research - Wed Dec 18, 5:57AM CST Zacks Equity Research - ZACKS - Wed Dec 18, 5:57AM CST
As of late, it has definitely been a great time to be an investor in ASLAN Pharmaceuticals.
Will ASLAN Continue to Surge Higher? Zacks Equity Research - Zacks Investment Research - Mon Nov 11, 6:09AM CST Zacks Equity Research - ZACKS - Mon Nov 11, 6:09AM CST
As of late, it has definitely been a great time to be an investor ASLAN Pharmaceuticals.
Ultragenyx (RARE) Reports Wider-Than-Expected Loss in Q3 Zacks Equity Research - Zacks Investment Research - Wed Nov 6, 10:00AM CST Zacks Equity Research - ZACKS - Wed Nov 6, 10:00AM CST
Ultragenyx (RARE) reports wider-than-expected loss and misses sales estimates in the third quarter of 2019.
Intercept (ICPT) Earnings and Sales Miss Estimates in Q3 Zacks Equity Research - Zacks Investment Research - Wed Nov 6, 9:34AM CST Zacks Equity Research - ZACKS - Wed Nov 6, 9:34AM CST
Intercept (ICPT) reports a wider-than-expected loss and misses on sales in the third quarter of 2019.
ASLAN Pharmaceuticals Ltd. (ASLN) Upgraded to Strong Buy: Here's Why Zacks Equity Research - Zacks Investment Research - Mon Jul 1, 8:00AM CDT Zacks Equity Research - ZACKS - Mon Jul 1, 8:00AM CDT
ASLAN Pharmaceuticals Ltd. (ASLN) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term....
ASLAN Pharmaceuticals Ltd. (ASLN) Upgraded to Buy: Here's Why Zacks Equity Research - Zacks Investment Research - Mon May 6, 8:00AM CDT Zacks Equity Research - ZACKS - Mon May 6, 8:00AM CDT
ASLAN Pharmaceuticals Ltd. (ASLN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Top Ranked Momentum Stocks to Buy for March 29th Zacks Equity Research - Zacks Investment Research - Fri Mar 29, 11:13AM CDT Zacks Equity Research - ZACKS - Fri Mar 29, 11:13AM CDT
Top Ranked Momentum Stocks to Buy for March 29th
Top Ranked Momentum Stocks to Buy for March 28th Zacks Equity Research - Zacks Investment Research - Thu Mar 28, 9:41AM CDT Zacks Equity Research - ZACKS - Thu Mar 28, 9:41AM CDT
Top Ranked Momentum Stocks to Buy for March 28th
ASLAN's Varlitinib Fails to Meet Endpoint in Phase II Study Zacks Equity Research - Zacks Investment Research - Mon Jan 14, 8:46AM CST Zacks Equity Research - ZACKS - Mon Jan 14, 8:46AM CST
ASLAN's (ASLN) varlitinib is unable to show any statistical significance for the primary endpoint in a phase II study with regard to first-line treatment of advanced or metastatic gastric cancer.
